We also showed that treatment of EphA3+ MSCs with the agonistic EphA3 antibody IIIA4 caused cytoskeletal collapse, reducing adhesion and cell viability in vitro, and prolonged treatment of mice bearing tumours resulted in disruption of the tumour stroma and decreased tumour growth. Here, EPHA3 is linked to neoplasm.